Clinical Trial Update: The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

This clinical trial update covers a Phase 2 study evaluating apatinib plus cytokine-induced killer (CIK) cell therapy as a third-line treatment for advanced gas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• CIK cell therapy (cytokine-induced killer cells)

Snippet

Sponsor: The First People's Hospital of Changzhou | Conditions: Stomach Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING